Clinical prognostic factors predicting survival of motor neuron disease patients with gastrostomy: A retrospective analysis.
gastrostomy
motor neuron disease
non-invasive ventilation
survival
weight
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
revised:
19
01
2024
received:
21
08
2023
accepted:
28
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
Enteral feeding via gastrostomy is a key intervention to prevent significant weight loss in Motor Neuron Disease (MND). The aim of this study was to explore demographic, clinical, and nutritional factors associated with survival time in MND patients with gastrostomy. The retrospective study analyzed 94 MND patients (n = 58 bulbar-onset and n = 36 limb-onset) who underwent gastrostomy between 2015 and 2021. The primary outcome was the survival time from gastrostomy insertion to death. Independent variables of interest explored were: age at gastrostomy insertion, disease onset type, known genetic cause, use of riluzole, non-invasive ventilation (NIV) use, forced vital capacity prior to gastrostomy, weight loss from diagnosis to gastrostomy insertion, and body mass index (BMI) at the time of gastrostomy insertion. The median survival time from gastrostomy to death was 357 days (± 29.3, 95%CI: 299.5, 414.5). Kaplan-Meier method and log-rank test revealed patients with lower body mass index <18.5 kg/m Preventing or minimizing weight loss from MND diagnosis and encouraging NIV use when clinically indicated are modifiable factors that may prolong the survival of MND patients with gastrostomy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Australian government research training program
Informations de copyright
© 2024 The Authors. Muscle & Nerve published by Wiley Periodicals LLC.
Références
López-Gómez JJ, Ballesteros-Pomar MD, Torres-Torres B, et al. Malnutrition at diagnosis in amyotrophic lateral sclerosis (als) and its influence on survival: using glim criteria. Clin Nutr (Edinburgh, Scotland). 2020;40(1):237-244. doi:10.1016/j.clnu.2020.05.014
Ning P, Yang B, Li S, et al. Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2019;20(5-6):356-367. doi:10.1080/21678421.2019.1587631
Heffernan C, Jenkinson C, Holmes T, et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(2):72-83.
National Clinical Guideline C. National Institute for health and care excellence: clinical guidelines. Motor Neurone disease: assessment and management. Health and Care Excellence (UK) Copyright © National Clinical Guideline Centre. National Institute for; 2016.
Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360-375. doi:10.1111/j.1468-1331.2011.03501.x
Kellogg J, Bottman L, Arra EJ, Selkirk SM, Kozlowski F. Nutrition management methods effective in increasing weight, survival time and functional status in ALS patients: a systematic review. Amyotroph Lateral Scler Front Degener. 2018;19(1-2):7-11. doi:10.1080/21678421.2017.1360355
Castanheira A, Swash M, De Carvalho M. Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review. Amyotroph Lateral Scler Front Degener. 2021;23:176-189. doi:10.1080/21678421.2021.1946089
Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(3):177-185. doi:10.1080/14660820310011728
Fasano A, Fini N, Ferraro D, Ferri L, Vinceti M, Mandrioli J. Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. Amyotroph Lateral Scler Front Degener. 2017;18(3-4):233-242. doi:10.1080/21678421.2016.1270325
Vergonjeanne M, Fayemendy P, Marin B, et al. Predictive factors for gastrostomy at time of diagnosis and impact on survival in patients with amyotrophic lateral sclerosis. Clin Nutr. 2020;39(10):3112-3118. doi:10.1016/j.clnu.2020.01.018
Progas Study G. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015;14(7):702-709. doi:10.1016/S1474-4422(15)00104-0
Stavroulakis T, Walsh T, Shaw PJ, et al. Gastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practice. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(2):96-104.
Heiman-Patterson T, Cudkowicz M, De Carvalho M, et al. Understanding the use of NIV in ALS: results of an international ALS specialist survey. Amyotroph Lateral Scler Front Degener. 2018;19(5-6):331-341. doi:10.1080/21678421.2018.1457058
Nagashima K, Furuta N, Makioka K, Fujita Y, Ikeda M, Ikeda Y. An analysis of prognostic factors after percutaneous endoscopic gastrostomy placement in Japanese patients with amyotrophic lateral sclerosis. J Neurol Sci. 2017;376:202-205. doi:10.1016/j.jns.2017.03.029
Carbo Perseguer J, Madejon Seiz A, Romero Portales M, et al. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis: mortality and complications. Neurologia (Barcelona, Spain). 2019;34(9):582-588. doi:10.1016/j.nrl.2018.01.003
Elbe P, Markus K, Valente R, Ingre C, Tsolakis AV, Vujasinovic M. Effectiveness of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis. Minerva Gastroenterol Dietol. 2020;66(3):219-224. doi:10.23736/S1121-421X.20.02695-1
Hesters A, Amador MDM, Debs R, et al. Predictive factors for prognosis after gastrostomy placement in routine non-invasive ventilation users ALS patients. Sci Rep. 2020;10(1):15117. doi:10.1038/s41598-020-70422-2
Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci. 1999;169(1-2):118-125. doi:10.1016/S0022-510X(99)00230-0
Pena MJ, Ravasco P, Machado M, et al. What is the relevance of percutaneous endoscopic gastrostomy on the survival of patients with amyotrophic lateral sclerosis? Amyotroph Lateral Scler. 2012;13(6):550-554. doi:10.3109/17482968.2012.684215
Strijbos D, Keszthelyi D, Gilissen LPL, et al. Percutaneous endoscopic versus radiologic gastrostomy for enteral feeding: a retrospective analysis on outcomes and complications. Endosc Int Open. 2019;7(11):E1487-E1495. doi:10.1055/a-0953-1524
Forbes RB, Colville S, Swingler RJ. Frequency, timing and outcome of gastrostomy tubes for amyotrophic lateral sclerosis/motor neurone disease-a record linkage study from the Scottish Motor Neurone Disease Register. J Neurol. 2004;251(7):813-817. doi:10.1007/s00415-004-0429-9
Chiò A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53(5):1123-1125. doi:10.1212/WNL.53.5.1123
Thompson AG, Blackwell V, Marsden R, et al. A risk stratifying tool to facilitate safe late-stage percutaneous endoscopic gastrostomy in ALS. Amyotroph Lateral Scler Front Degener. 2017;18(3-4):243-248. doi:10.1080/21678421.2016.1274330
Barone M, Viggiani MT, Introna A, et al. Nutritional prognostic factors for survival in amyotrophic lateral sclerosis patients undergone percutaneous endoscopic gastrostomy placement. Amyotroph Lateral Scler Front Degener. 2019;20(7-8):490-496. doi:10.1080/21678421.2019.1643374
Bokuda K, Shimizu T, Imamura K, et al. Predictive factors for prognosis following unsedated percutaneous endoscopic gastrostomy in ALS patients. Muscle Nerve. 2016;54(2):277-283. doi:10.1002/mus.25051
Bond L, Ganguly P, Khamankar N, et al. A comprehensive examination of percutaneous endoscopic gastrostomy and its association with amyotrophic lateral sclerosis patient outcomes. Brain Sci. 2019;9(9):223.
Daghlas SA, Govindarajan R, Consortium tPROAACT. Relative effects of forced vital capacity andALSFRS-Ron survival inALS. Muscle Nerve. 2021;64(3):346-351. doi:10.1002/mus.27344
Miller R, Jackson C, Kasarskis E, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218-1226. doi:10.1212/WNL.0b013e3181bc0141
Dorst J, Dupuis L, Petri S, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. J Neurol. 2015;262(4):849-858. doi:10.1007/s00415-015-7646-2
Spataro R, Ficano L, Piccoli F, la Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci. 2011;304(1):44-48. doi:10.1016/j.jns.2011.02.016
Walsh LJ, Deasy KF, Gomez F, et al. Use of non-invasive ventilation in motor neuron disease-a retrospective cohort analysis. Chron Respir Dis. 2021;18:1-9. doi:10.1177/14799731211063886
Ackrivo J, Hsu J, Hansen-Flaschen J, et al. Noninvasive ventilation use is associated with better survival in amyotrophic lateral sclerosis. Ann Am Thorac Soc. 2021;18(3):486-494. doi:10.1513/AnnalsATS.202002-169OC
Jackson C, Heiman-Patterson T, Sherman M, et al. Factors associated with noninvasive ventilation compliance in patients with ALS/MND. Amyotroph Lateral Scler Front Degener. 2021;22(suppl 1):40-47. doi:10.1080/21678421.2021.1917617
Rio A, Ellis C, Shaw C, et al. Nutritional factors associated with survival following enteral tube feeding in patients with motor neurone disease. J Hum Nutr Diet. 2010;23(4):408-415. doi:10.1111/j.1365-277X.2010.01057.x
Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler. 2006;7(1):16-21. doi:10.1080/14660820510012013